Display options
Cite
No HJ, Lester-Coll NH, Seward DJ, et al. Active Surveillance for Medically Inoperable Stage IA Lung Cancer in the Elderly. Cureus. 2018;10(10):e3472doi: 10.7759/cureus.3472.
No, H. J., Lester-Coll, N. H., Seward, D. J., Sidiropoulos, N., Gagne, H. M., Nelson, C. J., Garrison, G. W., Kinsey, C. M., Lin, S. H., & Anker, C. J. (2018). Active Surveillance for Medically Inoperable Stage IA Lung Cancer in the Elderly. Cureus, 10(10), e3472. https://doi.org/10.7759/cureus.3472
No, Hyunsoo J, et al. "Active Surveillance for Medically Inoperable Stage IA Lung Cancer in the Elderly." Cureus vol. 10,10 (2018): e3472. doi: https://doi.org/10.7759/cureus.3472
No HJ, Lester-Coll NH, Seward DJ, Sidiropoulos N, Gagne HM, Nelson CJ, Garrison GW, Kinsey CM, Lin SH, Anker CJ. Active Surveillance for Medically Inoperable Stage IA Lung Cancer in the Elderly. Cureus. 2018 Oct 22;10(10):e3472. doi: 10.7759/cureus.3472. PMID: 30648024; PMCID: PMC6318089.
Copy Download .nbib Format: NLM
Share it on

Cureus. 2018 Oct 22;10(10):e3472. doi: 10.7759/cureus.3472.

Active Surveillance for Medically Inoperable Stage IA Lung Cancer in the Elderly.

Cureus

Hyunsoo J No, Nataniel H Lester-Coll, David J Seward, Nikoletta Sidiropoulos, Havaleh M Gagne, Carl J Nelson, Garth W Garrison, C Matthew Kinsey, Steven H Lin, Christopher J Anker

Affiliations

  1. Radiation Oncology, Larner College of Medicine at the University of Vermont, Burlington, USA.
  2. Radiation Oncology, University of Vermont Cancer Center, Burlington, USA.
  3. Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont and the University of Vermont Health Network, Burlington, USA.
  4. Pulmonology and Critical Care Medicine, University of Vermont Medical Center, Burlington, USA.
  5. Pulmonary and Critical Care Medicine, University of Vermont Medical Center, Burlington, USA.
  6. Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.

PMID: 30648024 PMCID: PMC6318089 DOI: 10.7759/cureus.3472

Abstract

Objectives Treatment for stage IA lung cancer may be too aggressive an approach in elderly patients with competing co-morbidities. We report outcomes for those electing active surveillance (AS) and investigate factors that may predict indolent disease. Materials and methods Retrospective review was performed for 12 consecutive patients, ≥70 years old, with medically inoperable stage IA, T1N0M0 lung cancer and significant co-morbidities, who chose AS with radiation therapy (RT) reserved for clear disease progression. Collected data included Charlson-Deyo Comorbidity Index (CDCI) grades, histology, and tumor size changes. Volume doubling time (VDT) calculations used a modified Schwartz equation. Results Fifteen nodules underwent AS in 12 patients; three patients had more than one nodule. Median age of all patients was 78 (range, 71-85). All patients' CDCI grades were ≥1, 7 were ≥2. Eleven of 12 patients were deemed to be at high-risk for falls. Twelve nodules in 12 patients were biopsied; adenocarcinoma the prevailing common (47%) histology. The median, one, two and three year patient freedom-from-RT values were 21.4 months (95% CI: 11.6-not reached), 81%, 43%, and 29%, respectively. Median VDT of treated vs. untreated nodules was 189 days (range, 62-infinite) vs. 1153 days (range, 504-infinite), respectively. No patient progressed regionally or distantly, and there have been no cancer-related deaths. Due to cardiovascular events, two patients died and one remains on hospice. Median duration of AS for those still continuing computed tomography (CT) surveillance is 35.1 months. Conclusion Selected elderly patients with stage IA lung cancer and significant co-morbidities may undergo AS without detriment in outcome. Prospective AS studies are warranted.

Keywords: active surveillance; elderly; non-small cell lung cancer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

  1. Cancer. 2010 Jan 15;116(2):406-14 - PubMed
  2. N Engl J Med. 2011 Aug 4;365(5):395-409 - PubMed
  3. EJNMMI Res. 2012 Apr 24;2(1):16 - PubMed
  4. Ann Intern Med. 2013 Sep 17;159(6):411-420 - PubMed
  5. Clin Lung Cancer. 2014 Mar;15(2):131-5 - PubMed
  6. JAMA Intern Med. 2014 Feb 1;174(2):269-74 - PubMed
  7. Radiat Oncol. 2014 Jun 16;9:138 - PubMed
  8. Eur Respir J. 2015 Mar;45(3):765-73 - PubMed
  9. Clin Oncol (R Coll Radiol). 2016 Jan;28(1):28-35 - PubMed
  10. Am J Respir Crit Care Med. 2015 Nov 15;192(10):1208-14 - PubMed
  11. Cancer. 2015 Dec 1;121(23):4222-30 - PubMed
  12. Pract Radiat Oncol. 2016 Mar-Apr;6(2):e27-33 - PubMed
  13. Pract Radiat Oncol. 2016 Sep-Oct;6(5):367-374 - PubMed
  14. Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):900-907 - PubMed
  15. Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):893-899 - PubMed
  16. N Engl J Med. 2017 Jul 20;377(3):203-206 - PubMed
  17. J Geriatr Oncol. 2017 Sep;8(5):351-355 - PubMed

Publication Types